Equities analysts expect Stryker Co. (NYSE:SYK) to report $3.20 billion in sales for the current quarter, according to Zacks. Ten analysts have issued estimates for Stryker’s earnings. The lowest sales estimate is $3.15 billion and the highest is $3.24 billion. Stryker reported sales of $2.96 billion during the same quarter last year, which would suggest a positive year over year growth rate of 8.1%. The company is expected to report its next earnings report on Tuesday, April 24th.
According to Zacks, analysts expect that Stryker will report full-year sales of $3.20 billion for the current year, with estimates ranging from $13.32 billion to $13.67 billion. For the next fiscal year, analysts forecast that the business will report sales of $14.41 billion per share, with estimates ranging from $14.22 billion to $14.56 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Stryker.
Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, beating the consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The firm had revenue of $3.47 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the firm earned $1.78 EPS. Stryker’s revenue for the quarter was up 9.9% on a year-over-year basis.
SYK has been the subject of several research reports. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating and upped their price target for the company from $161.00 to $173.00 in a research report on Thursday, November 16th. JPMorgan Chase & Co. upgraded shares of Stryker from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Royal Bank of Canada restated a “buy” rating and set a $175.00 price objective on shares of Stryker in a research report on Tuesday, January 9th. Wells Fargo restated an “outperform” rating and set a $174.00 price objective (up previously from $166.00) on shares of Stryker in a research report on Tuesday, January 2nd. They noted that the move was a valuation call. Finally, Needham & Company LLC restated a “hold” rating on shares of Stryker in a research report on Thursday, December 7th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $164.76.
Stryker (NYSE SYK) traded up $1.06 during mid-day trading on Friday, reaching $167.51. 2,045,086 shares of the company traded hands, compared to its average volume of 1,379,062. Stryker has a 1 year low of $129.82 and a 1 year high of $170.00. The stock has a market cap of $62,332.94, a P/E ratio of 62.50, a price-to-earnings-growth ratio of 2.39 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.59 and a current ratio of 2.29.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be issued a $0.47 dividend. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.12%. Stryker’s dividend payout ratio is presently 70.15%.
In other news, VP William E. Berry, Jr. sold 1,306 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $164.42, for a total value of $214,732.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Yin C. Becker sold 23,221 shares of the stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $165.96, for a total transaction of $3,853,757.16. Following the completion of the transaction, the vice president now owns 10,499 shares of the company’s stock, valued at approximately $1,742,414.04. The disclosure for this sale can be found here. Insiders sold a total of 43,611 shares of company stock valued at $7,178,719 in the last quarter. Insiders own 7.40% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Retirement Systems of Alabama grew its stake in Stryker by 2.5% in the 3rd quarter. Retirement Systems of Alabama now owns 234,870 shares of the medical technology company’s stock valued at $33,356,000 after acquiring an additional 5,656 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its stake in Stryker by 3.1% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 55,255 shares of the medical technology company’s stock valued at $7,847,000 after acquiring an additional 1,683 shares during the last quarter. Signature Estate & Investment Advisors LLC grew its stake in Stryker by 5.7% in the 4th quarter. Signature Estate & Investment Advisors LLC now owns 14,958 shares of the medical technology company’s stock valued at $2,316,000 after acquiring an additional 804 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in Stryker in the 3rd quarter valued at about $538,000. Finally, State of Alaska Department of Revenue grew its stake in Stryker by 216.4% in the 4th quarter. State of Alaska Department of Revenue now owns 48,095 shares of the medical technology company’s stock valued at $7,445,000 after acquiring an additional 32,892 shares during the last quarter. Institutional investors and hedge funds own 75.71% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/zacks-brokerages-expect-stryker-co-syk-will-post-quarterly-sales-of-3-20-billion.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Get a free copy of the Zacks research report on Stryker (SYK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.